ArticleInternational journal of nanomedicine2018
Bioengineering the spider silk sequence to modify its affinity for drugs.
Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Bioengineered elastin- and silk-biomaterials for drug and gene delivery.Advanced drug delivery reviews · 2020Pooled it
- Phosphate- and pH-dependent self-assembly of recombinant spider silk proteins.Protein science : a publication of the Protein Society · 2026Article
- Nanostructured Protein Surfaces Inspired by Spider Silk.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- "Attractive" Treatment for Abdominal Aortic Aneurysm Repair: Magnetic Localization of Silk-Iron Packaged Extracellular Vesicles.Journal of functional biomaterials · 2025Article
- Preparation and characterization of a iRGD-modified recombinant spider silk particles for antitumor polypeptide drug delivery into cancer cells.BMC biotechnology · 2025Article
- Chemical Conjugation of Iron Oxide Nanoparticles for the Development of Magnetically Directable Silk Particles.ACS applied materials & interfaces · 2025Article
- Delivery of Polypeptide Drugs Using Nanoparticles Made of Recombinant Spider Silks Derived From MaSp4 Protein.International journal of nanomedicine · 2025Article
- Delivering on the promise of recombinant silk-inspired proteins for drug delivery.Advanced drug delivery reviews · 2023Review
- Bioengineering of spider silks for the production of biomedical materials.Frontiers in bioengineering and biotechnology · 2022Review
- Review
- Silk Particles as Carriers of Therapeutic Molecules for Cancer Treatment.Materials (Basel, Switzerland) · 2020Review
- Drug affinity and targeted delivery: double functionalization of silk spheres for controlled doxorubicin delivery into Her2-positive cancer cells.Journal of nanobiotechnology · 2020Article
- Composite spheres made of bioengineered spider silk and iron oxide nanoparticles for theranostics applications.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSilk is a biocompatible and biodegradable material, able to self-assemble into different morphological structures. Silk structures may be used for many biomedical applications, including carriers for drug delivery. The authors designed a new bioengineered spider silk protein, EMS2, and examined its property as a carrier of chemotherapeutics. MATERIALS AND
methodsTo obtain EMS protein, the MS2 silk monomer (that was based on the MaSp2 spidroin of
resultsThe bioengineered silk variant, EMS2, was constructed, produced, and purified. The EMS2 silk retained the self-assembly property and formed spheres. The spheres made of EMS2 and MS2 silks were not cytotoxic and had a similar secondary structure content but differed in morphology and zeta potential values; EMS2 particles were more negatively charged than MS2 particles. Independently of the loading method (pre- or post-loading), the loading of drugs into EMS2 spheres was more efficient than the loading into MS2 spheres. The advantageous loading efficiency and release rate made EMS2 spheres a good choice to deliver neutral etoposide (ETP). Despite the high loading efficiency of positively charged mitoxantrone (MTX) into EMS2 particles, the fast release rate made EMS2 unsuitable for the delivery of this drug. A faster release rate from EMS2 particles compared to MS2 particles was observed for positively charged doxorubicin (DOX).
conclusionBy modifying its sequence, silk affinity for drugs can be controlled.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.